Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | PTGER1 | P34995 | 11/20 | 0.55 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.53 |
| ▸ | STAT3 | P40763 | 1/20 | 0.52 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.51 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6360998 | 0.93 | KMT2A (0.60) | KMT2ANPC1ALDH1A1TP53RAB9A | |
| SCHEMBL6356805 | 0.91 | KMT2A (0.60) | KMT2ANPC1ALDH1A1TP53RAB9A | |
| SCHEMBL6356674 | 0.88 | KMT2A (0.57) | KMT2ANPC1ALDH1A1TP53RAB9A | |
| SCHEMBL6362768 | 0.87 | NPC1 (0.63) | KMT2ANPC1ALDH1A1TP53RAB9A | |
| SCHEMBL6358715 | 0.86 | PTGER1 (0.58) | KMT2APTGER1SGMS2AKR1C3HPGD | |
| SCHEMBL6360924 | 0.86 | NPC1 (0.56) | KMT2ANPC1ALDH1A1TP53RAB9A | |
| SCHEMBL6354467 | 0.86 | PTGER1 (0.55) | KMT2ANPC1ALDH1A1TP53RAB9A | |
| SCHEMBL6355187 | 0.86 | PTGER1 (0.59) | KMT2ANPC1ALDH1A1TP53RAB9A | |
| SCHEMBL6363241 | 0.84 | NPC1 (0.65) | KMT2ANPC1ALDH1A1TP53RAB9A | |
| SCHEMBL6361721 | 0.84 | PTGER1 (0.58) | KMT2APTGER1SGMS2AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050009812-A1 | Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-01-13 | — | — | US | claimed |
| EP-1438973-A1 | REMEDIES FOR STRESS DISEASES COMPRISING MITOCHONDRIAL BENZODIAZEPINE RECEPTOR ANTAGONISTS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-07-21 | — | — | EP | claimed |
| US-20050009812-A1 | Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-01-13 | — | — | US | disclosed |
| EP-1438973-A1 | REMEDIES FOR STRESS DISEASES COMPRISING MITOCHONDRIAL BENZODIAZEPINE RECEPTOR ANTAGONISTS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-07-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009812-A1 | Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists | TFAM, CYP11B2, CYP11B1 | KMT2A 1711/4885NPC1 719/4885ALDH1A1 1194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.